These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 36407022)
1. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Mathai S; Williams L Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022 [TBL] [Abstract][Full Text] [Related]
2. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620 [TBL] [Abstract][Full Text] [Related]
3. Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. Reyes KRL; Bilgili G; Rader F Heart Int; 2022; 16(2):91-98. PubMed ID: 36741099 [TBL] [Abstract][Full Text] [Related]
4. Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy. Packard E; de Feria A; Peshin S; Reza N; Owens AT Cardiol Ther; 2022 Dec; 11(4):491-507. PubMed ID: 36243823 [TBL] [Abstract][Full Text] [Related]
5. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217 [TBL] [Abstract][Full Text] [Related]
6. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D; Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100 [TBL] [Abstract][Full Text] [Related]
7. Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review. Aguiar T; Martins E Rev Port Cardiol; 2022 Aug; 41(8):693-703. PubMed ID: 36073269 [TBL] [Abstract][Full Text] [Related]
8. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Marian AJ Circ Res; 2021 May; 128(10):1533-1553. PubMed ID: 33983830 [TBL] [Abstract][Full Text] [Related]
9. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study. Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645 [TBL] [Abstract][Full Text] [Related]
10. Mavacamten - a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. Pysz P; Rajtar-Salwa R; Smolka G; Olivotto I; Wojakowski W; Petkow-Dimitrow P Kardiol Pol; 2021; 79(9):949-954. PubMed ID: 34268723 [TBL] [Abstract][Full Text] [Related]
11. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]
12. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706 [TBL] [Abstract][Full Text] [Related]
13. Small Molecules acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. Alsulami K; Marston S Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339418 [TBL] [Abstract][Full Text] [Related]